

PRESS RELEASE

Ad hoc announcement pursuant to article 53 LR

LEPU Medical Technology(Beijing) Announces Results for the Semi-annual of 2024

Beijing, China, August 24, 2024- LEPU Medical Technology(Beijing) Co.,Ltd.(the “Company”) today announced its performance for the six months ended June 30, 2024:

- During the reporting period, the Company realized an operating income of RMB 3383.8866 million, a net profit of RMB 697.2423 million attributable to shareholders of listed companies, a net profit of RMB 647.1473 million attributable to shareholders of listed companies after non-recurring gains and losses are deducted, and a net cash flow of RMB 158.8860 million from operating activities. At the end of the reporting period, the Company's total assets were RMB 25296.3977 million, and the net assets attributable to shareholders of listed companies were RMB 15890.9991 million, with a weighted average return on equity of 4.47%.
- During the reporting period, the operating income of cardiovascular intervention business was RMB 1151.4105 million, with a year-on-year increase of 16.92%, of which the operating income of coronary intervention business was RMB 850.6044 million, with a year-on-year increase of 10.21%; The structural heart disease business realized an operating income of RMB 248.9148 million, with a year-on-year increase of 53.63%. The operating income of surgical anesthesia business was RMB 268.6512 million, a year-on-year decrease of 3.87%. The in vitro diagnostic business achieved operating income of RMB 197.6766 million, a year-on-year decrease of 57.15%, mainly due to the high base of epidemic-related products in the same period last year and the intensified competition of some products and the price drop.

- During the reporting period, the pharmaceutical sector realized an operating income of RMB 1134.6522 million, including RMB 938.8257 million for preparations (generic drugs) and RMB 195.8265 million for active pharmaceutical ingredients. Even though the company has recently transformed and increased its weight in related R&D, it will add a dermatology injection R&D pipeline in 2022, and in 2023, it will take a stake in Shanghai Minwei Biotech, a cardiovascular innovative drug company, and finally achieve a controlling stake. As a result, the company was unable to resist the impact of the relevant policies of the retail channel on the net sales and delivery of some products. At this stage, the prosperity of the physical pharmacy industry is affected by the policy, and the willingness to purchase is reduced, even if the company has made a distinction between the online and offline channels in the hospital and outside the hospital, the phenomenon of channeling goods occurs from time to time, and the decline in product bargaining power and poor channel price control have caused the net sales of some products to be greatly affected by relevant policies. At present, it is judged that the adjustment of the drug business brought about by the inventory clearance of the retail channel may need to last for 1-2 quarters, and the whole year is expected to include the API business, the overall drug year-on-year basically remains stable, and the operating income of the preparation sector business may fall to about 1.5-1.6 billion.
- During the reporting period, the medical care solutions segment achieved operating income of RMB 495.5669 million, a year-on-year decrease of 27.80%. Based on the adjustment of the business segment from the strategic point of view, Lepu Yunzhi Technology achieved an operating income of RMB 261.7748 million, a year-on-year decrease of 29.17%, mainly due to the decline in the demand for household-related medical device products for vital indication monitoring at home and abroad in the post-epidemic era, and the company's requirements for this business are changing from continuous and continuous revenue increase to stable profitability. Hefei Cardiovascular Hospital achieved an operating income of RMB

80.6125 million, a year-on-year increase of 17.25%. **Financial**

Results(unaudited)

	This reporting period	Same period of last year	Increase or decrease in this reporting period over the same period of last year
Operating revenue (RMB)	3,383,886,554.54	4,301,457,705.65	-21.33%
Net profits attributable to shareholders of the listed company (RMB)	697,242,271.91	961,487,273.99	-27.48%
Net profits attributable to shareholders of the Company after deducting non-recurring profits and losses (RMB)	647,147,330.31	904,874,709.56	-28.48%
Net cash flow generated from operating activities (RMB)	158,886,015.01	141,701,593.18	12.13%
Basic revenues per share (RMB/share)	0.3766	0.5163	-27.06%
Diluted earnings per share (RMB/share)	0.3766	0.5147	-26.83%
Weighted average return on equity	4.47%	6.39%	a decrease of 1.92 percentage
	End of this report	End of last year	Increase or decrease at the end of this reporting period compared with the end of last year
Total assets (RMB)	25,296,397,719.60	25,022,331,486.69	1.10%
Net assets attributable to shareholders of the listed company (RMB)	15,890,999,052.04	15,976,101,963.31	-0.53%

Full third quarter report

The full 2024 Semi-annual Report as of and for the six months ended June 30, 2024 is available on our website at <https://en.lepumedical.com/investors/>.

Contact information

Ms. Weina Jiang

Phone: +86 010 80120622

E-mail: zqb@lepumedical.com

About LEPU

LEPU Medical Technology(Beijing) Co.,Ltd was the total-solution provider in the PRC across the full life cycle of cardiovascular disease management, with products and services encompassing medical devices, pharmaceuticals, and medical care solutions. Company is one of the earliest companies in the PRC to offer coronary interventional products and have consolidated our first-mover advantage through relentless innovation since our inception in 1999. Our key products, namely, coronary drug-eluting stent, coronary bioresorbable scaffold, coronary drug-coated balloon, congenital heart disease occluder and coronary cutting balloon. Our leading R&D expertise and capabilities have enabled us to develop and successfully commercialize a comprehensive portfolio of products. We focus our R&D efforts on unmet clinical needs. We have developed and commercialized the first fully biodegradable occluder in the world and many first Chinese brand products, such as coronary stent, cardiac pacemaker, bioresorbable scaffold and coronary cutting balloon. In addition, we are the first PRC company to apply AI technology to ECG devices. Furthermore, benefiting from our diverse technology platforms, we have developed over 80 product candidates for cardiovascular devices and peripheral artery devices across coronary artery diseases, structural heart diseases, cardiac rhythm management, electrophysiology and other segments.

Disclaimers

This announcement contains forward-looking statements, estimates, opinions and projections with respect to anticipated future performance of the Company ("forward-looking statements"). These forward-looking statements can be identified by the use of forward looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements

are based on the current views, expectations and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release.